BridgeBio
BBIO
$65.04
-2.20%
BridgeBio Pharma is a commercial-stage biotechnology company focused on discovering, developing, and delivering transformative treatments for patients with genetic diseases, with a pipeline spanning Mendelian disorders, oncology, and gene therapy. Its lead commercial asset, Attruby (acoramidis), is an orally administered transthyretin stabilizer approved for transthyretin amyloid cardiomyopathy (ATTR-CM), positioning the company as a direct competitor to Pfizer's tafamidis and Alnylam's RNAi-based Amvuttra in a multi-billion-dollar market. The investor narrative has shifted decisively from pipeline speculation to commercial execution: Attruby's launch trajectory, a successful Phase 3 achondroplasia (dwarfism) program with an FDA filing planned, and a deep late-stage pipeline are driving bullish sentiment, with 21 analysts covering the name and a consensus strong buy. However, the debate remains sharply two-sided — bulls point to a 101% year-over-year revenue increase and a $4.7 billion consensus revenue estimate, while bears highlight persistent GAAP losses, deeply negative free cash flow, and a stock that has fallen roughly 12% over the past month despite the fundamental progress.…
BBIO
BridgeBio
$65.04
Related headlines
Investment Opinion: Should I buy BBIO Today?
The synthesized recommendation is Hold. While the analyst consensus is strong buy with an average target of $109.10 (62% upside), the company's precarious cash position and negative free cash flow introduce near-term uncertainty that tempers the bullish case. The core thesis is that Attruby's commercial success is real and accelerating, but the stock's premium valuation and financing needs create a balanced risk/reward at the current price of $67.25.
Supporting evidence includes: 1) Revenue growth of 101.18% YoY in Q2 2026, with revenue reaching $222.44 million; 2) Gross margin of 93.24%, indicating strong pricing power; 3) Analyst consensus of strong buy with 21 analysts and a target range of $80–$157; 4) The PS ratio has compressed from 97.85x to 30.05x, showing improving valuation relative to growth. However, free cash flow TTM is -$592.12 million, and cash of $377.71 million provides less than two quarters of runway, making a capital raise likely.
The biggest risks that could invalidate the thesis are: 1) A dilutive equity offering that pressures the stock price; 2) Slower-than-expected Attruby sales due to competition from Alnylam and Pfizer; 3) A delay or failure in the achondroplasia FDA filing. The rating would upgrade to Buy if the company secures non-dilutive financing or achieves positive operating cash flow, and would downgrade to Sell if revenue growth decelerates below 50% YoY or if cash burn accelerates. Relative to its history, the stock is fairly valued on a PS basis, but relative to peers, it is overvalued; thus, the Hold rating reflects this dichotomy.
Sign up to view all
BBIO 12-Month Price Forecast
The forward view is balanced: BridgeBio's commercial launch is exceeding expectations, but the company's financial position is precarious. The stock's 30x PS multiple is high relative to peers but reasonable relative to its own history, and the analyst consensus is overwhelmingly positive. However, the need for near-term financing and competitive threats create a risk/reward that is roughly symmetric at the current price. I would upgrade to bullish if the company secures non-dilutive funding or demonstrates a clear path to profitability, and downgrade to bearish if revenue growth decelerates or cash burn accelerates.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on BridgeBio's 12-month outlook, with a consensus price target around $109.05 and implied upside of +67.7% versus the current price.
Average Target
$109.05
0 analysts
Implied Upside
+67.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$80 - $156
Analyst target range
Coverage is robust, with 21 analysts covering BBIO and a consensus recommendation of strong buy (recommendation mean of 1.5, where 1.0 is a strong buy and 5.0 is a sell). The average target price is $109.10, which implies approximately 62% upside from the current price of $67.25. The consensus is overwhelmingly bullish — the institutional ratings data shows a uniform wall of Buy/Overweight/Outperform ratings from HC Wainwright, Mizuho, Canaccord Genuity, JP Morgan, Truist, Wells Fargo, Morgan Stanley, TD Cowen, and B of A Securities, with no downgrades or sell ratings in the recent record. The consensus EPS estimate of $10.35 for the forward period, against a current quarterly loss of $0.78, underscores the market's expectation of a dramatic profitability inflection.
The target range is wide, from a low of $80.00 to a high of $157.00 — a spread of $77.00, or roughly 96% of the low target. Even the most conservative analyst sees 19% upside from the current price, while the most bullish sees 133% upside. The high target of $157 likely assumes rapid Attruby market-share gains in ATTR-CM, successful expansion into the achondroplasia market following the Phase 3 win, and multiple expansion as the company approaches profitability. The low target of $80 prices in slower launch momentum, competitive pressure from Alnylam and Pfizer, and continued cash burn requiring dilution. The wide spread signals high uncertainty, which is typical for a commercial-stage biotech with a binary pipeline — but the fact that the lowest target is still 19% above the current price suggests analysts view the recent 12% pullback as a buying opportunity rather than a fundamental deterioration. The absence of any downgrades in the recent ratings record reinforces that the sell-side remains firmly in the bull camp.
Bulls vs Bears: BBIO Investment Factors
The bull case rests on explosive revenue growth (101% YoY), exceptional gross margins (93.24%), and a strong analyst consensus with 62% upside to the average target. The bear case centers on unsustainable cash burn (-$592 million TTM FCF), persistent GAAP losses (-68% net margin), and a valuation (30x PS) that prices in flawless execution. Currently, the bear evidence carries more weight because the company's cash runway of less than two quarters introduces near-term financing risk that could dilute shareholders or force unfavorable terms. The single most important tension is whether Attruby's revenue ramp can outpace operating expenses before the balance sheet becomes a constraint; if revenue growth sustains above 80% YoY while operating margin improves, the bull case prevails, but any deceleration could trigger a sharp re-rating given the premium valuation.
Bullish
- Revenue accelerating at triple-digit pace: Q2 2026 revenue of $222.44 million grew 101.18% year-over-year from $110.57 million, marking the fifth consecutive quarter of sequential growth. The ramp from $5.88 million in Q4 2024 to $222.44 million in Q2 2026 demonstrates that Attruby is scaling rapidly in the ATTR-CM market.
- Exceptional gross margins and pricing power: Gross margin stands at 93.24% (gross profit of $207.39 million on $222.44 million revenue), well above the typical biotech range. This confirms strong pricing power for Attruby and provides substantial operating leverage as revenue scales.
- Strong analyst consensus with 62% upside: 21 analysts rate BBIO a strong buy (mean 1.5), with an average target price of $109.10, implying 62% upside from $67.25. Even the lowest target of $80.00 represents 19% upside, and there are no sell ratings in the recent record.
- Pipeline optionality from achondroplasia program: The successful Phase 3 trial in achondroplasia with an FDA filing planned for 2026 provides a second major growth driver. This expands the addressable market beyond ATTR-CM and could drive significant revenue diversification.
Bearish
- Deeply negative free cash flow and cash burn: TTM free cash flow is -$592.12 million, with Q2 2026 free cash flow of -$223.78 million. Cash at end of Q2 2026 was $377.71 million, down from $882.02 million in Q1 2026, implying less than two quarters of runway at the current burn rate.
- Persistent GAAP losses despite revenue growth: Q2 2026 net income was -$152.22 million, a net margin of -68.43%, and EPS of -$0.78. Operating expenses of $314.47 million (including $149.45 million R&D and $186.26 million G&A) continue to overwhelm gross profit.
- Extreme valuation premium to sector: The PS ratio of 30.05x and EV/Sales of 22.08x are 200–600% above the typical commercial-stage biotech range of 5–10x sales. This premium leaves little room for execution missteps.
- Negative shareholder equity and high leverage: Debt-to-equity is -1.31 due to negative shareholders' equity, and the current ratio of 2.62 masks a quick ratio of 1.17. The company relies on capital markets, having raised $549.89 million in net financing in Q1 2026.
BBIO Technical Analysis
BBIO is in a choppy, range-bound consolidation with a modest longer-term upward bias. The stock is up 26.22% over the past year but sits at $67.25, only about 36% of the way up its 52-week range of $52.00 to $93.415 — meaning it is trading far closer to its annual low than its high despite the positive 1-year return. That positioning reflects a stock that made its highs in July 2026 (peaking at $90.17 on July 9) and has since given back most of those gains, suggesting the market is no longer pricing in momentum but rather waiting for the next fundamental catalyst. With a beta of 0.971, BBIO is roughly as volatile as the broader market, which is unusually low for a commercial-stage biotech and implies the stock's risk is currently more idiosyncratic (pipeline/launch execution) than systematic.
Short-term momentum is clearly negative and diverging from the longer-term trend. The stock is down 12.09% over the past month and 12.88% over three months, versus a 1-year gain of 26.22% — a classic deceleration pattern where recent selling pressure is eroding the annual return. Relative strength confirms the underperformance: BBIO trails SPY by 12.68 percentage points over 1 month, 16.22 points over 3 months, and 25.42 points over 6 months, even though it outperformed SPY by 11.21 points over the full year. Year-to-date the stock is down 14.04%, and the 27.28% maximum drawdown from its July peak underscores how violent the reversal has been. The most recent session showed a modest bounce (+0.51% to $67.25 on 2.65 million shares), but this is a single green candle within a clear downtrend, not yet a reversal signal.
Key technical levels are well defined. Support sits at the 52-week low of $52.00, roughly 23% below the current $67.25 price, while resistance is the 52-week high of $93.415, about 39% above. A breakdown below the $65–$66 area (which has been tested repeatedly in late September) would open the door to a retest of the $52 low and likely trigger momentum-driven selling; a breakout above $80 would signal that the July correction has run its course and could set up a move back toward the $90s. With a beta of 0.971 and a short ratio of 10.61 — meaning it would take over 10 days of average volume to cover all short positions — the stock carries meaningful squeeze potential on any positive catalyst, but also elevated vulnerability to further downside if sentiment sours.
Beta
0.97
0.97x market volatility
Max Drawdown
-27.9%
Largest decline past year
52-Week Range
$53-$93
Price range past year
Annual Return
+17.6%
Cumulative gain past year
| Period | BBIO Return | S&P 500 |
|---|---|---|
| 1m | -13.0% | +1.0% |
| 3m | -24.3% | +2.5% |
| 6m | -12.8% | +13.9% |
| 1y | +17.6% | +15.0% |
| ytd | -16.9% | +13.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BBIO Fundamental Analysis
BridgeBio's revenue trajectory has inflected dramatically, driven by the Attruby launch. Q2 2026 revenue was $222.44 million, up 101.18% year-over-year from $110.57 million in Q2 2025, and up sequentially from $194.52 million in Q1 2026 and $154.18 million in Q4 2025. The multi-quarter trend is unambiguously accelerating: revenue has grown from just $5.88 million in Q4 2024 to $120.70 million in Q3 2025, $154.18 million in Q4 2025, $194.52 million in Q1 2026, and $222.44 million in Q2 2026. Product revenue of $222.44 million dominates the mix, with royalty revenue of $15.43 million and license/service revenue of $5.80 million, confirming that the commercial franchise — not one-time licensing — is now the growth engine. This is the single most important fact in the investment case: BBIO has transitioned from a pre-revenue biotech to a commercial-stage company with a rapidly scaling top line.
Profitability remains the central problem. Q2 2026 net income was -$152.22 million on $222.44 million of revenue, a net margin of -68.43%, and EPS of -$0.78. Gross margin is exceptionally high at 93.24% (gross profit of $207.39 million), which is typical for a branded pharmaceutical and confirms strong pricing power, but operating expenses of $314.47 million — including $149.45 million in R&D and $186.26 million in G&A — overwhelm the gross profit. The loss has narrowed slightly from Q1 2026's -$164.04 million and Q4 2025's -$197.24 million, and the operating margin improved from -120.14% in Q4 2025 to -48.14% in Q2 2026, but the company is still burning substantial cash. The key question for investors is whether revenue growth can outpace expense growth before the balance sheet becomes a constraint; at the current trajectory, the gap is narrowing but not yet closed.
Balance sheet and cash flow metrics reveal a company funding its launch externally. Free cash flow TTM is -$592.12 million, with Q2 2026 free cash flow of -$223.78 million and operating cash flow of -$223.33 million. Cash at end of Q2 2026 was $377.71 million, down sharply from $882.02 million at the end of Q1 2026, reflecting the $608.41 million debt repayment in Q1 and ongoing operating burn. The current ratio of 2.62 and quick ratio of 1.17 suggest adequate near-term liquidity, but the debt-to-equity ratio of -1.31 (negative because shareholders' equity is negative) and ROE of 35.12% (also distorted by negative equity) make traditional leverage metrics unreliable. The company raised $549.89 million in net financing in Q1 2026 and issued $28.06 million in common stock, indicating reliance on capital markets. With a cash balance of $377.71 million against a quarterly burn of roughly $220 million, BBIO has less than two quarters of runway at the current pace — making the Attruby revenue ramp and any additional financing a critical near-term focus.
Quarterly Revenue
$222440000.0B
2026-06
Revenue YoY Growth
+101.2%
YoY Comparison
Gross Margin
93.2%
Latest Quarter
Free Cash Flow
$-592121000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BBIO Overvalued?
Because BridgeBio reported negative net income (Q2 2026 net income of -$152.22 million, trailing EPS of -$0.048), the PE ratio is not meaningful — the trailing PE of -20.18 and forward PE of 2,448.13 are both distorted and should be disregarded. The appropriate primary metric is the price-to-sales ratio: BBIO trades at a PS of 30.05x on trailing revenue and an EV/Sales of 22.08x. The forward PE of 2,448x reflects the market's expectation that the company will swing to profitability, but the magnitude of that multiple signals how far current earnings are from justifying the valuation. The gap between the trailing PS of 30x and the forward earnings-based valuation implies the market is pricing in a dramatic earnings inflection — consistent with the consensus 2026 EPS estimate of $10.35, which would represent a massive turnaround from the current -$0.78 quarterly loss.
Relative to the biotechnology sector, BBIO's 30x PS is a significant premium to the typical biotech trading range of roughly 5–10x sales for commercial-stage companies, though it is not unusual for a high-growth launch story. The EV/Sales of 22.08x is more moderate and reflects the company's debt load. The premium is partially justified by the 101% year-over-year revenue growth and the 93.24% gross margin, which are well above sector norms, but it also embeds substantial execution risk: the company must sustain triple-digit growth while simultaneously closing a -48% operating margin gap. Compared to large-cap biotech peers trading at 4–8x sales with similar or better profitability, BBIO's 30x PS represents a 200–600% premium, which leaves little room for disappointment.
Historically, BBIO's PS ratio has been extremely volatile, ranging from 18.06x in Q2 2022 to 4,350x in Q3 2022 (when revenue was near zero) and 883.74x in Q4 2024. The current 30.05x is near the low end of the company's own historical range, which is a direct consequence of revenue scaling faster than the share price. This is a critical nuance: the stock is not expensive relative to its own history — it is expensive relative to the sector. The compression from 97.85x PS in Q4 2025 to 30.05x in Q2 2026 reflects the revenue ramp, and if growth continues at the current pace, the multiple will compress further without any change in share price. The valuation debate therefore hinges entirely on whether the revenue trajectory is sustainable.
PE
-20.2x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-25.6x
Enterprise Value Multiple
Investment Risk Disclosure
BridgeBio faces significant financial and operational risks. The company burned $223.78 million in free cash flow in Q2 2026 alone, and with only $377.71 million in cash, it has less than two quarters of runway at the current pace. This creates a high probability of near-term capital raising, which could dilute existing shareholders or increase debt. Additionally, revenue is heavily concentrated in a single product, Attruby, which competes directly with Pfizer's tafamidis and Alnylam's Amvuttra in the ATTR-CM market; any loss of market share or pricing pressure would severely impact the growth trajectory. The negative debt-to-equity ratio of -1.31 and negative shareholders' equity further limit financial flexibility.
Market and competitive risks are substantial. BBIO trades at a PS ratio of 30.05x, a 200–600% premium to the typical commercial-stage biotech range of 5–10x sales, leaving it vulnerable to valuation compression if growth slows. The beta of 0.971 indicates the stock moves roughly in line with the broader market, but its idiosyncratic risk is elevated due to binary pipeline events. Competitive threats are intensifying: Alnylam's RNAi platform and Pfizer's established tafamidis franchise could erode Attruby's market share, and the recent news about BioMarin's royalty deal in achondroplasia highlights the competitive landscape for BBIO's pipeline. Regulatory hurdles for the achondroplasia program also pose risks, as FDA approval is not guaranteed.
The worst-case scenario involves a combination of slowing Attruby sales, a failed or delayed achondroplasia filing, and a dilutive financing round. If revenue growth decelerates below 50% YoY and the company is forced to raise capital at depressed prices, the stock could retest its 52-week low of $52.00, representing a 23% decline from the current price of $67.25. The analyst low target of $80.00 is above the current price, but in a severe bear case, the stock could fall to the 52-week low or lower, implying a potential loss of 23% or more. The maximum drawdown of 27.28% from the July peak already demonstrates the stock's vulnerability to sharp reversals.
FAQ
The key risks for BBIO are ranked as follows: 1) Financial risk: The company has less than two quarters of cash runway at the current burn rate, with free cash flow of -$592 million TTM, making a dilutive capital raise highly likely. 2) Competitive risk: Attruby faces intense competition from Alnylam's Amvuttra and Pfizer's tafamidis in the ATTR-CM market, and any market share loss could severely impact growth. 3) Valuation risk: The stock trades at a PS ratio of 30x, a 200-600% premium to peers, leaving it vulnerable to sharp declines if growth slows. 4) Pipeline risk: The achondroplasia program, while promising, faces regulatory hurdles, and a delay or rejection could remove a key growth catalyst. These risks are significant and should be carefully weighed.
Our 12-month forecast for BBIO includes three scenarios. The bull case (30% probability) targets $120-$157, assuming Attruby continues to gain share, the achondroplasia program is approved, and the company achieves profitability ahead of schedule. The base case (50% probability) targets $90-$110, aligning with the analyst average of $109.10, assuming steady revenue growth and successful financing. The bear case (20% probability) targets $52-$80, reflecting competitive pressures, dilutive financing, and regulatory delays. The most likely scenario is the base case, with a key assumption that revenue growth remains above 70% YoY and the company secures necessary funding without excessive dilution. The wide target range reflects the high uncertainty inherent in a commercial-stage biotech.
BBIO's valuation is nuanced. On a price-to-sales basis, it trades at 30.05x, which is a significant premium to the typical commercial-stage biotech range of 5-10x sales. However, this premium is partially justified by its 101% revenue growth and 93.24% gross margin, which are well above sector norms. Relative to its own history, the PS ratio has compressed from 97.85x in Q4 2025 to 30.05x in Q2 2026, indicating that the stock is not expensive compared to its past. The forward PE of 2,448x is distorted due to expected profitability, but the consensus EPS estimate of $10.35 for 2026 implies a massive turnaround. Overall, the stock appears overvalued relative to peers but fairly valued relative to its growth trajectory, leaving little margin for error.
BBIO presents a compelling but risky investment case. The company's revenue is growing at 101% year-over-year, driven by the successful launch of Attruby, and analysts see 62% upside to their average target of $109.10. However, the company is burning significant cash, with negative free cash flow of $592 million TTM and only $377.71 million in cash, implying less than two quarters of runway. This makes a dilutive financing likely, which could pressure the stock. For investors with a high risk tolerance and a long-term horizon, BBIO could be a good buy on dips, but it is not suitable for conservative portfolios. The risk/reward is balanced at the current price of $67.25, with potential upside to $109 but downside to $52 if execution falters.
BBIO is more suitable for long-term investment than short-term trading. The company is in a growth phase with a commercial launch that is still in its early innings, and the full potential of Attruby and the pipeline will take years to materialize. The stock's beta of 0.971 indicates it is roughly as volatile as the market, but its idiosyncratic risk is high due to binary events like FDA approvals and financing needs. There is no dividend, so returns depend entirely on capital appreciation. Short-term trading is risky due to the potential for sharp moves on news. A minimum holding period of 2-3 years is recommended to allow for revenue ramp, pipeline development, and potential profitability. Investors should be prepared for volatility and possible dilution along the way.